As part of the international competition E-Rare-3 European Research Projects on Rare Diseases, the ARSACS project entitled "PREPARE" led by Dr. Matthis Synofzik (Germany) was selected for phase 2 of the competition.Read more
Anti-Sacsin Antibody now available through Millipore(product # ABN1019). For more information, click Millipore.
An interdisciplinary conference on neuromuscular diseases and amyotrophic lateral sclerosis was held on April 16 & 17. This event was attended by professionals who specialize in the care of patients with neuromuscular disease and ALS. ARSACS was the topic of discussion at several occasions.Read more
An international working group held a meeting in the UK on March 25, 2015 to discuss clinical measures that could be used to establish the efficacy of drugs in the treatment of Ataxia of Charlevoix-Saguenay.Read more
Update on Dr. Synofzik's research "A randomised delayed entry trial of intensive home-based speech therapy in ARSACS" project funded by the Foundation.Read more
Dr. Jonathon Burman, Ph.D.researcher(Research Fellow) will study the role of the Sacsin on human cells. Dr. Burman is part of Dr. Richard Youle's research lab at the National Institutes of Health (NIH) Maryland, USA. See Dr. Burman's project abstract.
Preliminary discussions are underway with an american pharmaceutical cie to test a drug for ARSACS (preclinical trial). More information to follow.
The Ataxia Charlevoix-Saguenay Foundation was founded in 2006 to finance scientific research on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).Learn more
Again this year, with Mr. Jacques Bougie as the honorary president, the Dîner des Producteurs had a great success raising over $700,000 for the ARSACS reseach.Learn more
ARSACS is a debilating hereditary and progressive childhood neurological disorder.Learn more